1. SPRY2 deficiency leads to CRPC
SPRY2 deficiency leads to CRPC AKaplan–Meier plot for the relapse‐free survival of prostate cancer patients treated with androgen deprivation therapy (ADT). SPRY2‐high patients, n = 14; SPRY2‐low patients, n = 13; log‐rank (Mantel–Cox) test; P =  BKaplan–Meier plot for overall (post‐diagnosis) survival of ADT‐treated prostate cancer patients. SPRY2‐high patients, n = 12; SPRY2‐low patients, n = 7; log‐rank (Mantel–Cox) test; P =  CRepresentative images for immunostaining for SPRY2 in HN (hormone‐naïve) and CRPC (castration‐resistant prostate cancer) matched clinical prostate cancer sections. Scale bars = 100 μm.DImmunostaining for SPRY2 in HN and CRPC matched clinical prostate cancer sections represented as IHC (immunohistochemistry) scores (n = 35 pairs; paired two‐tailed Student's t‐test; *P = 0.0009).ERepresentative H&E and immunostained images of prostate sections from Nkx3.1 Ptenfl/+Spry2fl/+ (NPS) mice. Scale bars = 100 μm.FProstate tumour burden 1 month post‐ADT in NPS mice (n = 6 mice per group; unpaired two‐tailed Student's t‐test; *P = 0.0009).GProstate tumour burden at clinical endpoint in NPS mice (n = 5 mice per group).H, IGrowth rate of LNCaP control and SPRY2‐overexpressing cells (H); and CWR22Res Nsi (non‐silencing) control and CL3 and Pool stable SPRY2 knockdown cell lines (I) relative to T0 (Day 0) in hormone‐proficient (FBS) medium and hormone‐depleted (CSS) medium (n = 3; *P < 0.05; ANOVA Tukey's test).JCWR22Res prostate orthograft tumour volumes from 60‐days timed experiment (n = 5 mice per group; *P < 0.05; ANOVA Tukey's test).KThe effects of ADT on the CWR‐22 prostate orthografts from 60‐days timed experiment represented as % necrosis/tumour weight (n = 5 mice per group; *P < 0.05; ANOVA Tukey's test).Data Information: In (D, F, G, J, K), each data point represents one independent observation. In (H, I), each data point is mean of three independent observations. In (D, F, G–K), data are presented as mean ± SD.
Rachana Patel et al. EMBO Mol Med. 2018;10:e8347
© as stated in the article, figure or figure legend